Prediction and identification of HLA-A*0201-restricted epitopes from cancer testis antigen CT23

References

• Salmaninejad A, Zamani MR, Pourvahedi M, Golchehre Z, Hosseini BA, Rezaei N. Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest. 2016;45(7):619–12. doi:10.1080/08820139.2016.1197241.
   PubMed Web of Science ®Google Scholar
• Gibbs ZA, Whitehurst AW. Emerging contributions of cancer/testis antigens to neoplastic behaviors. Trends Cancer. 2018;4(10):701–712. doi:10.1016/j.trecan.2018.08.005.
   PubMed Web of Science ®Google Scholar
• Fan C, Qu H, Wang X, Sobhani N, Wang L, Liu S, Xiong W, Zeng Z, Li Y. Cancer/testis antigens: from serology to mRNA cancer vaccine. Semin Cancer Biol. 2021;76:218–31. doi:10.1016/j.semcancer.2021.04.016.
   PubMed Web of Science ®Google Scholar
• Meng X, Sun X, Liu Z, He Y. A novel era of cancer/testis antigen in cancer immunotherapy. Int Immunopharmacol. 2021;98:107889. doi:10.1016/j.intimp.2021.107889.
   PubMed Web of Science ®Google Scholar
• Nin DS, Deng LW. Biology of cancer-testis antigens and their therapeutic implications in cancer. Cells. 2023;12(6):926. doi:10.3390/cells12060926.
   PubMed Web of Science ®Google Scholar
• Ren S, Zhang Z, Li M, Wang D, Guo R, Fang X, Chen F. Cancer testis antigen subfamilies: attractive targets for therapeutic vaccine (review). Int J Oncol. 2023;62(6):71. doi:10.3892/ijo.2023.5519.
   PubMed Web of Science ®Google Scholar
• Jäger E, Gnjatic S, Nagata Y, Stockert E, Jäger D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide- vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA. 2000 Oct 24;97(22):12198–203. doi:10.1073/pnas.220413497.
   PubMed Web of Science ®Google Scholar
• Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999 Jan 18;80(2):219–30. doi:10.1002/(SICI)1097-0215(19990118)80:2<219:AID-IJC10>3.0.CO;2-S.
   PubMed Web of Science ®Google Scholar
• Ono T, Kurashige T, Harada N, Noguchi Y, Saika T, Niikawa N, Aoe M, Nakamura S, Higashi T, Hiraki A, et al. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci USA. 2001;98(6):3282–7. doi:10.1073/pnas.041625098.
   PubMed Web of Science ®Google Scholar
• Whitehurst AW, Xie Y, Purinton SC, Cappell KM, Swanik JT, Larson B, Girard L, Schorge JO, White MA. Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation. Cancer Res. 2010;70(19):7652–61. doi:10.1158/0008-5472.CAN-10-0840.
   PubMed Web of Science ®Google Scholar
• Fu J, Luo B, Guo WW, Zhang QM, Shi L, Hu QP, Chen F, Xiao SW, Xie XX. Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro. Int J Clin Exp Pathol. 2015;8:7786–7797.
   PubMed Web of Science ®Google Scholar
• Ning W, Huang M, Wu S, Wang H, Yao J, Ge Y, Tang Y, Sun K, Xie X, Hu Q. CT23 knockdown attenuating malignant behaviors of hepatocellular carcinoma cell is associated with upregulation of metallothionein 1. Cell Biol Int. 2021;45(6):1231–1245. doi:10.1002/cbin.11567.
   PubMed Web of Science ®Google Scholar
• Lin L, Nong W, Luo B, Ge Y, Zeng X, Li F, Fan R, Zhang Q, Xie X. Cancer-testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: its association with prognosis. Immun Inflamm Dis. 2021;9(4):1759–1770. doi:10.1002/iid3.534.
   PubMed Web of Science ®Google Scholar
• Li X, Yan J, Fan R, Luo B, Zhang Q, Lin Y, Zhou S, Luo G, Xie X, Xiao S. Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma. Oncol Lett. 2017;13(5):3080–6. doi:10.3892/ol.2017.5799.
   PubMed Web of Science ®Google Scholar
• Luo B, Yun X, Fan R, Lin YD, He SJ, Zhang QM, Mo FR, Chen F, Xiao SW, Xie XX. Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters. Int J Clin Exp Pathol. 2013;6:2835–2845.
   PubMed Web of Science ®Google Scholar
• Fan R, Huang W, Luo B, Zhang QM, Xiao SW, Xie XX. Cancer testis antigen OY-TES-1: analysis of protein expression in ovarian cancer with tissue microarrays. Eur J Gynaecol Oncol. 2015;36:298–303.
   PubMed Web of Science ®Google Scholar
• Luo B, Yun X, Li J, Fan R, Guo WW, Liu C, Lin YD, Ge YY, Zeng X, Bi SQ, et al. Cancer-testis antigen OY-TES-1 expression and immunogenicity in hepatocellular carcinoma. Curr Med Sci. 2020;40(4):719–728. doi:10.1007/s11596-020-2241-x.
   PubMed Web of Science ®Google Scholar
• Feola S, Chiaro J, Martins B, Cerullo V. Uncovering the tumor antigen landscape: what to know about the discovery process. Cancers Basel. 2020 Jun 23;12(6):1660. doi:10.3390/cancers12061660.
   PubMed Web of Science ®Google Scholar
• Liang B, Zhu L, Liang Z, Weng X, Lu X, Zhang C, Li H, Wu X. A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China. Cell Mol Immunol. 2006;3:453–458.
   PubMed Web of Science ®Google Scholar
• Tang B, Zhou W, Du J, He Y, Li Y. Identification of human leukemia antigen A*0201-restricted epitopes derived from epidermal growth factor pathway substrate number 8. Mol Med Rep. 2015;12(2):1741–1752. doi:10.3892/mmr.2015.3673.
   PubMed Web of Science ®Google Scholar
• Bonsack M, Hoppe S, Winter J, Tichy D, Zeller C, Küpper MD, Schitter EC, Blatnik R, Riemer AB. Performance evaluation of MHC class-I binding prediction tools based on an experimentally validated MHC-peptide binding dataset.Cancer Immunol Res. 2019;7(5):719–736. doi:10.1158/2326-6066.CIR-18-0584.
   Google Scholar
• Rosendahl Huber SK, Luimstra JJ, van Beek J, Hoppes R, Jacobi RH, Hendriks M, Kapteijn K, Ouwerkerk C, Rodenko B, Ovaa H, et al. Chemical Modification of Influenza CD8+T-Cell Epitopes Enhances Their Immunogenicity Regardless of Immunodominance. PLoS ONE. 2016 Jun 22;11(6):e0156462. doi:10.1371/journal.pone.0156462.
   PubMed Web of Science ®Google Scholar
• Okumura H, Noguchi Y, Uenaka A, Aji T, Ono T, Nakagawa K, Aoe M, Shimizu N, Nakayama E. Identification of an HLA-A24-restricted CT23 epitope recognized by cytotoxic T cell. Microbiol Immunol. 2005;49(11):1009–1016. doi:10.1111/j.1348-0421.2005.tb03688.x.
   PubMed Web of Science ®Google Scholar
• Bi SQ, Zhang QM, Zeng X, Liu C, Nong WX, Xie H, Li F, Lin LN, Luo B, Ge YY, et al. Combined treatment with epigenetic agents enhances anti-tumor activity of MAGE-D4 peptide-specific T cells by upregulating the MAGE-D4 expression in glioma. Front Oncol. 2022 Aug 3;12:873639. doi:10.3389/fonc.2022.873639.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhai M, Wu Z, Qi Y, Wu Y, Dai C, Sun M, Li L, Gao Y. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer. Amino Acids. 2012;42(6):2257–2265. doi:10.1007/s00726-011-0966-3.
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, McBride WH, Economou JS. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol. 2001;166(8):5300–5308. doi:10.4049/jimmunol.166.8.5300.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wan T, Zhou X, Wang B, Yang F, Li N, Chen G, Dai S, Liu S, Zhang M, et al. Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine. Cancer Res. 2005;65(11):4947–4954. doi:10.1158/0008-5472.CAN-04-3912.
   PubMed Web of Science ®Google Scholar
• Chen Q, Jia G, Zhao X, Bao Y, Zhang Y, Ozkan C, Minev B, Ma W. Novel survivin peptides screened with computer algorithm induce cytotoxic T lymphocytes with higher cytotoxic efficiency to cancer cells. Front Mol Biosci. 2020 Sep 2;7:570003. doi:10.3389/fmolb.2020.570003.
   PubMed Web of Science ®Google Scholar
• Li J, Bai J, Gu L, He A, Wang J, Wang J, Zhang P, Zhang W. Prediction and identification of HLA-A*0201-restricted epitopes from leukemia-associated protein MLAA-22 which elicit cytotoxic T lymphocytes. Med Oncol. 2014;31(12):293. doi:10.1007/s12032-014-0293-0.
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509–21. doi:10.1002/jcp.27782.
   PubMed Web of Science ®Google Scholar
• Khandelwal N, Breinig M, Speck T, Michels T, Kreutzer C, Sorrentino A, Sharma AK, Umansky L, Conrad H, Poschke I, et al. A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. EMBO Mol Med. 2015;7(4):450–463. doi:10.15252/emmm.201404414.
   PubMed Web of Science ®Google Scholar
• Sari G, Rock KL. Tumor immune evasion through loss of MHC class-I antigen presentation. Curr Opin Immunol. 2023 Aug;83:102329. doi:10.1016/j.coi.2023.102329.
   PubMed Web of Science ®Google Scholar
• Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21(5):298–312. doi:10.1038/s41568-021-00339-z.
   PubMed Web of Science ®Google Scholar
• Safavi A, Kefayat A, Sotoodehnejadnematalahi F, Salehi M, Modarressi MH. Production, purification, and in vivo evaluation of a novel multiepitope peptide vaccine consisted of immunodominant epitopes of SYCP1 and ACRBP antigens as a prophylactic melanoma vaccine. Int Immunopharmacol. 2019;76:105872. doi:10.1016/j.intimp.2019.105872.
   PubMed Web of Science ®Google Scholar
• Safavi A, Kefayat A, Mahdevar E, Ghahremani F, Nezafat N, Modarressi MH. Efficacy of co-immunization with the DNA and peptide vaccines containing SYCP1 and ACRBP epitopes in a murine triple-negative breast cancer model. Hum Vaccin Immunother. 2021;17(1):22–34. doi:10.1080/21645515.2020.1763693.
   PubMed Web of Science ®Google Scholar
• Bi SQ, Zhang QM, Zeng X, Liu C, Nong WX, Xie H, Li F, Lin LN, Luo B, Ge YY, et al. Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma. Am J Transl Res. 2021;13:7591–7609.
   PubMed Web of Science ®Google Scholar
• Najafi S, Mortezaee K. Advances in dendritic cell vaccination therapy of cancer. Biomed Pharmacother. 2023;164:114954. doi:10.1016/j.biopha.2023.114954.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang X, Yu Y, Xu Z, Sun Y, Liu H, Cheng J, Liu M, Sha B, Li L, et al. Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells. J Cancer. 2018 Jan 1;9(2):275–287. doi:10.7150/jca.22176.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang J, Wang Q, Yang Y, Guo J, Ren C, Mou Y, Jia C, Song X, Song X. Laryngeal extra-skeletal Ewing sarcoma treated with DC-CTL immunotherapy: a case report and review of the literature. Front Oncol. 2022 Nov 30;12:1003393. doi:10.3389/fonc.2022.1003393.
   PubMed Web of Science ®Google Scholar
• Ren PT, Zhang Y. Comparative investigation of the effects of specific antigensensitized DCCIK and DCCTL cells against B16 melanoma tumor cells. Mol Med Rep. 2017;15(4):1533–1538. doi:10.3892/mmr.2017.6175.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu Z, Zhou F, Sun Y, Chen J, Li L, Jin H, Qian Q. The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors. Exp Hematol Oncol. 2015 Nov 10;4(1):32. doi:10.1186/s40164-015-0027-9.
   PubMedGoogle Scholar
• Zhong G, Zhao W, Li Y, Jin G, Zeng W, Yu C, Zhou J, Yu L. MAGEA1 and hTERT Peptide treatment improves the potency of the dendritic cell- cytotoxic T lymphocytes (DC-CTL) immunotherapy in DAC treated acute myeloid leukemia. J Cancer. 2022 Jan 24;13(4):1252–1260. doi:10.7150/jca.66501.
   PubMed Web of Science ®Google Scholar
• Wei X, Chen F, Xin K, Wang Q, Yu L, Liu B, Liu Q. Cancer-testis antigen peptide vaccine for cancer immunotherapy: progress and prospects. Transl Oncol. 2019;12(5):733–8. doi:10.1016/j.tranon.2019.02.008.
   PubMed Web of Science ®Google Scholar
• Liao F, Zhang J, Hu Y, Najafabadi AH, Moon JJ, Wicha MS, Kaspo B, Whitfield J, Chang AE, Li Q. Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells. Cancer Immunol Immunother. 2022;71(8):1959–73. doi:10.1007/s00262-021-03129-6.
   PubMed Web of Science ®Google Scholar
• Zeng JZ, Liu Y, Huang F, He ZH, Sun H, Lu YD, Lei JH, Luo RC. Glypican-3-specific cytotoxic T lymphocytes induced by human leucocyte antigen-A*0201-restricted peptide effectively kill hepatocellular carcinoma cells in vitro. Asian Pac J Trop Med. 2017 Nov;10(11):1084–9. doi:10.1016/j.apjtm.2017.10.013.
   PubMed Web of Science ®Google Scholar
• Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. 2021 Mar 9;12:636568. doi:10.3389/fimmu.2021.636568.
   PubMed Web of Science ®Google Scholar
• Cornel AM, Mimpen IL, Nierkens S. MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers Basel. 2020 Jul 2;12(7):1760. doi:10.3390/cancers12071760.
   PubMed Web of Science ®Google Scholar
• Gocher AM, Workman CJ, Vignali DAA. Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22(3):158–72. doi:10.1038/s41577-021-00566-3.
   PubMed Web of Science ®Google Scholar
• Morrison BJ, Steel JC, Morris JC. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of cancer-initiating cells. BMC Cancer. 2018 Apr 26;18(1):469. doi:10.1186/s12885-018-4389-3.
   PubMedGoogle Scholar
• Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, Mortini P, Ferrone S, Doglioni C, Marincola FM, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res. 2010;16(3):800–813. CCR-09-2730. doi:10.1158/1078-0432.CCR-09-2730.
   PubMed Web of Science ®Google Scholar
• Liao T, Kaufmann AM, Qian X, Sangvatanakul V, Chen C, Kube T, Zhang G, Albers AE. Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines. J Cancer Res Clin Oncol. 2013;139(1):159–70. doi:10.1007/s00432-012-1311-2.
   PubMed Web of Science ®Google Scholar
• Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, Zahnow CA, Nickels ML, Liu F, Tantawy MN, et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun. 2018 Jan 16;9(1):248. doi:10.1038/s41467-017-02630-w.
   PubMed Web of Science ®Google Scholar
• Ritter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, Ugurel S, Schrama D, Becker JC. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Sci Rep. 2017 May 23;7(1):2290. doi:10.1038/s41598-017-02608-0.
   PubMedGoogle Scholar
• Demel, UM, Böger M, Yousefian S, Grunert C, Zhang L, Hotz PW, Gottschlich A, Köse H, Isaakidis K, Vonficht D, et al. Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer. J Clin Invest. 2022;132(9):e152383. doi:10.1172/JCI152383.
   PubMed Web of Science ®Google Scholar